AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. ONON
6. AAPL
7. RTB
8. AZN
9. SPCX
10. TRMD

Go back to AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
AbbVie (NYSE: ABBV) Delayed: 263.96 -0.06 (0.02%)
Previous Close $264.02    52 Week High $68.12 
Open $263.29    52 Week Low $50.71 
Day High $266.34    P/E 57.26 
Day Low $262.44    EPS $4.61 
Volume 8,176,594